Redesign Health’s Post

We are celebrating the successful closing of an additional $2.32 Million in Seed Plus funding, closing this round out $500,000 oversubscribed at $5 Million to address underserved #pelvichealth issues. This milestone reflects progress toward our mission to empower women & clinicians with a new gold standard in conservative care for #urinaryincontinence. We extend our deep appreciation to our outstanding partner, Boomerang Ventures for leading this investment round, and we warmly welcome new investors Pier 70 Ventures, Life Science Angels, Orange County Tech Coast Angels MedTech, and Blue Pacific Capital! "Completing this round is an important step in continuing Pelvital's unwavering dedication to provide women with innovative solutions for pelvic health, including the treatment of SUI," says Lydia Zeller, President and CEO of Pelvital. "This funding will play a crucial role in accelerating our commercialization of Flyte with a strong emphasis on expanding payor coverage, enhancing clinical education and clinician awareness, and advocating for upstream screening for UI in primary care and OB/GYN." With this close we are honored to welcome Preetha Ram, PhD, Managing Partner at Pier 70 Ventures, to the Pelvital Board of Directors.   "Joining Pelvital's Board alongside this investment round is truly an honor," she shares. "Pier 70 and I are thrilled to be part of this transformational opportunity, as Pelvital's mission aligns beautifully with our dedication to support disruptive technologies that shake up the status quo in healthcare. Pelvital's pioneering work is shaping a future where women's health receives the attention and innovation it deserves with novel medical devices like Flyte." With two published clinical trials validating Flyte's efficacy, we're excited to offer a groundbreaking treatment option for women. Learn more at Flytetherapy.com. #funding #Innovation #WomenInHealthcare Read the full release here: https://lnkd.in/ggkavYRq

Big day in my world folks - my company, Abridge, which uses #genAI to unburden clinicians from documentation just announced our Series B raise of $30M!!! What does this mean? 1. Scale: we get to move even faster to get this tech into the hands of docs, APPs and more 2. We ARE flipping the script and empowering more clinicians to spend more time on patients, not paperwork 3. We have the right partners to design together the highest priority frontiers of AI to automate low-value work, e.g. pre-templating orders, improving communication with patients 4. We can continue to expand our 'academic' footprint and prove the impact of this tech on reducing cognitive load/ #burnout /improving #patientexperience, not just in a white paper way, but in a peer-reviewed research way Hang on to your hats folks!!! Healthcare really is getting disrupted. Sreekanth Chaguturu Michelle Peluso Sachin H. Jain, MD, MBA Deepa Sheth John Halamka, M.D., M.S. So excited to work with you!!

I’m just three years, the impact is impressive. “Since we launched our product in 2021, we’ve diagnosed over 3,250,000 medical conditions that may have been missed without our tech.” Imagine where we will be in three more years, when this technology is not only used by physicians, but clinicians across the healthcare space. AI continues to augment individual’s work and the capabilities are clearly expressed in the outcomes. With daily news of healthcare organizations adopting various technologies, is yours keeping up with the pace? #clinicaloutcomes #improvinglives

“Inventing products — lots of people can do that. Innovating means actually getting it out into the world and making an impact, and it requires so much more than just a good problem statement and engineering. To really innovate, particularly in this healthcare system, you have to understand what it takes to get people access to the care and actually scale it.” Meet Kirsten Carroll, a strong leader with a quarter-century of expertise in #medicaldevices for neurovascular disorders. With a unique blend of academic and professional experience, including roles at Boston Scientific, Stryker, and Imperative Care, Kirsten is now leading the latter's spinout -Kandu Health™ which aims to significantly increase the quality of life of stroke survivors and their care partners. The impact? A startling 85% of the first 40 participants in Kandu's initial program were living independently by day 90. Amazing! 🔥 Here are some key insights from Kristen’s Medsider interview with Scott Nelson: ➡ To optimize for a fulfilling career in medtech, you need to continuously develop your skill sets. Take a layered approach to your decision-making, build a robust foundation of knowledge, and then trust your gut. 💗 ➡ Make sure the voices of your end users are heard. Kirsten's advisory board included stroke survivors who helped design and validate the product, every step of the way. 🙆🏾♀️ ➡ When taking on significant initiatives, adopt a process-oriented approach, break down big challenges into manageable, winnable steps, and build a team around you that is fully aligned with the mission. 📑 Check out the full interview where Kirsten shares her fresh approach to tackling the complexities of post-stroke care: (link in comments) This Medsider episode was brought to you by FastWave Medical, a hot IVL startup in the cardiovascular space. They closed their last capital raise in just a few weeks, so don’t miss out on the next one!  See more details in the comments below. PS - We just launched exciting new features exclusively for Medsider premium members: ⭐ Playbooks: Go from 0 to 100 with hand-picked collections of the best Medsider interviews with the brightest founders and CEOs. ⭐ Investor database: Find your next medical device or health technology investor with our growing database of VC funds, equity investors, and high-net-worth angels. You can find links to both in the comments below.

An absolutely critical note to let our investors know how much we appreciate them. Impact investors have helped to build our company by investing truly patient capital. A combination of impact funds and impact angel investors took a risk and invested their capital in a company with a powerful vision and an experienced team. By investing in Maternova they deployed their capital into a new structure that allowed them to spread their risk across a curated set of 40+ innovations in women's health, Femtech and neonatal health. Instead of picking a standalone company and investing in one technology and facing commercialization of a single product in the global market, these investors rallied behind a platform that spread the risk across multiple products, carved out channels to procurement agencies and GPOs alike. Eventually, they will get their investment back with a return, but while they wait, we are speeding the path to market for a growing set of obstetric and neonatal technologies. And each month and year that the products are registered in country and delivered in advance represents lives saved. Thank you to our extraordinary investors in this journey.

Congratulations Wellen and Bone Health Technologies - we always love seeing women's health companies join forces! P.S - if you want to learn more about Wellen, check out Eva Epker's Forbes article about the company right here ➡️ https://lnkd.in/gEEzN2eC #healthcare #womenshealth #osteoporosis #artificalintelligence #AI #mergersandacquisitions

Octagos Health | The Future of Digital Health, a Houston-based company specializing in AI-driven cardiac device monitoring solutions, has raised over $43 million in Series B funding. The investment round was led by Morgan Stanley Expansion Capital, with additional participation from Mucker Capital and other strategic investors. This significant capital infusion will be utilized to accelerate enhancements to Octagos Health's platform, which likely involves improving its AI capabilities and expanding its cardiac monitoring features. Additionally, the company plans to scale up its commercial team and operations, suggesting a push for market expansion and increased adoption of its technology. This funding round underscores investor confidence in Octagos Health's innovative approach to cardiac care and positions the company for substantial growth in the digital health and medical device monitoring sectors. https://lnkd.in/def6dqst

“We’re bringing some of the most innovative companies into the ecosystem here at Cleveland Clinic,” says Todd Schwarzinger, Partner at Cleveland Clinic Ventures, in a new article by Healthcare Brew focusing on how health systems are turning to internal venture capital (VC) arms to bring in additional revenue. Todd comments on how Cleveland Clinic is seeing a number of its portfolio companies begin to mature. One of the companies working in cancer diagnostics, Cleveland Diagnostics, Inc. recently closed a $75 million funding round—the largest single raise of a Cleveland Clinic portfolio company to date. As health systems face numerous financial challenges coming out of the pandemic, this innovative source of revenue helps to bridge the gaps. https://hubs.li/Q02rJqZm0 #innovation #clevelandclinic #ClevelandClinicInnovations #healthcareinnovation #healthsystems #venturecapital

Congratulations to Heritas' portfolio company Holmusk for raising additional US$30m funding from Veradigm®! This funding builds on the Series B round completed earlier this year also led by Veradigm and participated by Heritas alongside Health Catalyst Capital (HCC), Novartis (dRx Capital), and Northwell Holdings, the venture investment arm of Northwell Health, as well as other previous investors. This strategic collaboration draws on the strengths of each company to fuel innovation in #behavioralhealth and create the evidence needed to move the field forward. In this new phase of collaboration, cohorts of millions of behavioral health patients and related de-identified clinical data from Veradigm will be added to Holmusk’s NeuroBlu Database, a leading source for real-world data that shows how behavioral health care is delivered. The NeuroBlu Database will now be able to power even more research and address challenging behavioral health questions that require the creation of targeted research cohorts. Read more on the strategic investment below.

👋 Today, we welcome Shape Memory Medical to our Health portfolio! Our Earlybird Health team led the company's USD 38 M Series C financing with the participation of new and existing investors, including HBM Partners AG, Wexford Capital LP, MedFocus Fund, and Emergent Medical Partners. Shape Memory Medical develops innovative therapeutic solutions with its proprietary shape memory polymers for endovascular applications, addressing conditions such as abdominal aortic aneurysm (AAA). Its devices are approved in over 25 countries spanning regions in Asia, the Middle East, Europe, the Americas, and Australia. 🔬 “Shape Memory Medical’s approach to embolization is highly differentiated. At Earlybird Health, we support companies with breakthrough technologies and robust, positive patient outcomes. With 35 million people worldwide affected by AAA, leading to 150,000-200,000 annual deaths due to rupture, Shape Memory Medical’s innovative concepts for managing aortic aneurysms have the potential to be transformative in treating this condition,” comments Partner Thom Rasche. 👀 Find the press release at: https://bit.ly/48DcuE3 With: Edward (Ted) Ruppel, Mary Dennehy, John Yianni, Dr. Christoph Massner, Junkai Z. #EBVCgang #Healthcare #AAA #SeriesC #Startups